139 related articles for article (PubMed ID: 19665289)
21. Persistence, immune specificity, and functional ability of murine mutant ras epitope-specific CD4(+) and CD8(+) T lymphocytes following in vivo adoptive transfer.
Bristol JA; Schlom J; Abrams SI
Cell Immunol; 1999 May; 194(1):78-89. PubMed ID: 10357883
[TBL] [Abstract][Full Text] [Related]
22. Vaccination with human HER-2/neu (435-443) CTL peptide induces effective antitumor immunity against HER-2/neu-expressing tumor cells in vivo.
Gritzapis AD; Mahaira LG; Perez SA; Cacoullos NT; Papamichail M; Baxevanis CN
Cancer Res; 2006 May; 66(10):5452-60. PubMed ID: 16707474
[TBL] [Abstract][Full Text] [Related]
23. Adoptive immunotherapy using human peripheral blood lymphocytes transferred with RNA encoding Her-2/neu-specific chimeric immune receptor in ovarian cancer xenograft model.
Yoon SH; Lee JM; Cho HI; Kim EK; Kim HS; Park MY; Kim TG
Cancer Gene Ther; 2009 Jun; 16(6):489-97. PubMed ID: 19096447
[TBL] [Abstract][Full Text] [Related]
24. Cytotoxic effects of T cells induced by fusion protein 6B11-pulsed dendritic cells on ovarian carcinoma cells.
Yang W; Feng J; Chang X; Fu T; Ye X; Zhang H; Li X; Wen H; Feng L; Tong C; Cui H
Gynecol Oncol; 2007 Apr; 105(1):238-43. PubMed ID: 17383546
[TBL] [Abstract][Full Text] [Related]
25. Identification of an interferon-gamma-inducible carcinoembryonic antigen (CEA) CD8(+) T-cell epitope, which mediates tumor killing in CEA transgenic mice.
Schmitz J; Reali E; Hodge JW; Patel A; Davis G; Schlom J; Greiner JW
Cancer Res; 2002 Sep; 62(17):5058-64. PubMed ID: 12208761
[TBL] [Abstract][Full Text] [Related]
26. Anti-Her-2/neu-IL-2 or heregulin-IL-2 fusions proteins redirect non-tumor specific CTL to the tumor site for tumor eradication.
Lustgarten J
Cancer Immunol Immunother; 2003 Dec; 52(12):751-60. PubMed ID: 12827309
[TBL] [Abstract][Full Text] [Related]
27. Depletion of IL-10- and TGF-beta-producing regulatory gamma delta T cells by administering a daunomycin-conjugated specific monoclonal antibody in early tumor lesions augments the activity of CTLs and NK cells.
Seo N; Tokura Y; Takigawa M; Egawa K
J Immunol; 1999 Jul; 163(1):242-9. PubMed ID: 10384122
[TBL] [Abstract][Full Text] [Related]
28. [Immunotherapeutic efficacy of both helper T lymphocytes and cytotoxic T lymphocytes epitopes augmented dendritic cells tumor vaccine on gastric cancer].
Li Q; Zhang Y; Chen XH; Cao WX; Gu QL; Zhu ZG; Liu BY
Zhonghua Wei Chang Wai Ke Za Zhi; 2006 Mar; 9(2):148-51. PubMed ID: 16555158
[TBL] [Abstract][Full Text] [Related]
29. Immunogenic HLA-B*0702-restricted epitopes derived from human telomerase reverse transcriptase that elicit antitumor cytotoxic T-cell responses.
Adotévi O; Mollier K; Neuveut C; Cardinaud S; Boulanger E; Mignen B; Fridman WH; Zanetti M; Charneau P; Tartour E; Lemonnier F; Langlade-Demoyen P
Clin Cancer Res; 2006 May; 12(10):3158-67. PubMed ID: 16707616
[TBL] [Abstract][Full Text] [Related]
30. Ii-Key/HPV16 E7 hybrid peptide immunotherapy for HPV16+ cancers.
Xu M; Lu X; Sposato M; Zinckgraf JW; Wu S; von Hofe E
Vaccine; 2009 Jul; 27(34):4641-7. PubMed ID: 19520206
[TBL] [Abstract][Full Text] [Related]
31. Anti-tumor effects of immunotherapeutic peptide on the treatment of hepatocellular carcinoma with HBc carrier.
Kong J; Diao Z; Deng X; Zhong H; Yao W; Hu X
Oncol Rep; 2007 Jul; 18(1):279-85. PubMed ID: 17549380
[TBL] [Abstract][Full Text] [Related]
32. Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme.
Bondurant KL; Crew MD; Santin AD; O'Brien TJ; Cannon MJ
Clin Cancer Res; 2005 May; 11(9):3446-54. PubMed ID: 15867247
[TBL] [Abstract][Full Text] [Related]
33. Tumor-specific Ab-mediated targeting of MHC-peptide complexes induces regression of human tumor xenografts in vivo.
Lev A; Noy R; Oved K; Novak H; Segal D; Walden P; Zehn D; Reiter Y
Proc Natl Acad Sci U S A; 2004 Jun; 101(24):9051-6. PubMed ID: 15184663
[TBL] [Abstract][Full Text] [Related]
34. [GammadeltaT cell therapy].
Tanaka Y; Okamura H
Nihon Rinsho; 2012 Dec; 70(12):2147-51. PubMed ID: 23259388
[TBL] [Abstract][Full Text] [Related]
35. A novel antibody-like TCRγδ-Ig fusion protein exhibits antitumor activity against human ovarian carcinoma.
Zheng J; Guo Y; Ji X; Cui L; He W
Cancer Lett; 2013 Dec; 341(2):150-8. PubMed ID: 23920126
[TBL] [Abstract][Full Text] [Related]
36. Diverse solid tumors expressing a restricted epitope of L1-CAM can be targeted by chimeric antigen receptor redirected T lymphocytes.
Hong H; Stastny M; Brown C; Chang WC; Ostberg JR; Forman SJ; Jensen MC
J Immunother; 2014; 37(2):93-104. PubMed ID: 24509172
[TBL] [Abstract][Full Text] [Related]
37. Identification of human T cell receptor gammadelta-recognized epitopes/proteins via CDR3delta peptide-based immunobiochemical strategy.
Chen H; He X; Wang Z; Wu D; Zhang H; Xu C; He H; Cui L; Ba D; He W
J Biol Chem; 2008 May; 283(18):12528-37. PubMed ID: 18321859
[TBL] [Abstract][Full Text] [Related]
38. Cytotoxic effects of gammadelta T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy.
Sato K; Kimura S; Segawa H; Yokota A; Matsumoto S; Kuroda J; Nogawa M; Yuasa T; Kiyono Y; Wada H; Maekawa T
Int J Cancer; 2005 Aug; 116(1):94-9. PubMed ID: 15756684
[TBL] [Abstract][Full Text] [Related]
39. CDR3δ -grafted γ9δ2T cells mediate effective antitumor reactivity.
Zhao H; Xi X; Cui L; He W
Cell Mol Immunol; 2012 Mar; 9(2):147-54. PubMed ID: 21909128
[TBL] [Abstract][Full Text] [Related]
40. A novel multi-epitope vaccine from MMSA-1 and DKK1 for multiple myeloma immunotherapy.
Lu C; Meng S; Jin Y; Zhang W; Li Z; Wang F; Wang-Johanning F; Wei Y; Liu H; Tu H; Su D; He A; Cao X; Zhou F
Br J Haematol; 2017 Aug; 178(3):413-426. PubMed ID: 28508448
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]